RATIONALE: Animal models aimed to mimic mania have in common the lack of genuine affective parameters. Although rodent amphetamine-induced hyperlocomotion is a frequently used behavioral model of mania, locomotor activity is a rather unspecific target for developing new pharmacological therapies, and does not necessarily constitute a cardinal symptom in bipolar disorder (BD). Hence, alternative behavioral markers sensitive to stimulants are required. OBJECTIVES: Since D-amphetamine induces appetitive 50-kHz ultrasonic vocalizations (USV) in rats, we asked whether established or potential antimanic drugs would inhibit this effect, thereby possibly complementing traditional analysis of locomotor activity. METHODS: Amphetamine-treated rats (2.5 mg/kg) were systemically administered with the antimanic drugs lithium (100 mg/kg) and tamoxifen (1 mg/kg). Since protein kinase C (PKC) activity has been implicated in the pathophysiology of bipolar disorder and the biochemical effects of mood stabilizers, the new PKC inhibitor myricitrin (10, 30 mg/kg) was also evaluated. RESULTS: We demonstrate for the first time that drugs with known or potential antimanic activity were effective in reversing amphetamine-induced appetitive 50-kHz calls. Treatments particularly normalized amphetamine-induced increases of frequency-modulated calls, a subtype presumably indicative of positive affect in the rat. CONCLUSIONS: Our findings suggest that amphetamine-induced 50-kHz calls might constitute a marker for communicating affect that provides a useful model of exaggerated euphoric mood and pressured speech. The antimanic-like effects of the PKC inhibitors tamoxifen and myricitrin support the predictive and etiological validity of both drugs in this model and highlight the role of PKC signaling as a promising target to treat mania and psychosis-related disorders.
RATIONALE: Animal models aimed to mimic mania have in common the lack of genuine affective parameters. Although rodent amphetamine-induced hyperlocomotion is a frequently used behavioral model of mania, locomotor activity is a rather unspecific target for developing new pharmacological therapies, and does not necessarily constitute a cardinal symptom in bipolar disorder (BD). Hence, alternative behavioral markers sensitive to stimulants are required. OBJECTIVES: Since D-amphetamine induces appetitive 50-kHz ultrasonic vocalizations (USV) in rats, we asked whether established or potential antimanic drugs would inhibit this effect, thereby possibly complementing traditional analysis of locomotor activity. METHODS:Amphetamine-treated rats (2.5 mg/kg) were systemically administered with the antimanic drugs lithium (100 mg/kg) and tamoxifen (1 mg/kg). Since protein kinase C (PKC) activity has been implicated in the pathophysiology of bipolar disorder and the biochemical effects of mood stabilizers, the new PKC inhibitor myricitrin (10, 30 mg/kg) was also evaluated. RESULTS: We demonstrate for the first time that drugs with known or potential antimanic activity were effective in reversing amphetamine-induced appetitive 50-kHz calls. Treatments particularly normalized amphetamine-induced increases of frequency-modulated calls, a subtype presumably indicative of positive affect in the rat. CONCLUSIONS: Our findings suggest that amphetamine-induced 50-kHz calls might constitute a marker for communicating affect that provides a useful model of exaggerated euphoric mood and pressured speech. The antimanic-like effects of the PKC inhibitors tamoxifen and myricitrin support the predictive and etiological validity of both drugs in this model and highlight the role of PKC signaling as a promising target to treat mania and psychosis-related disorders.
Authors: Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Jorge Quiroz; Libby Jolkovsky; David A Luckenbaugh; Husseini K Manji Journal: Bipolar Disord Date: 2007-09 Impact factor: 6.744
Authors: Tilo Kircher; Markus Wöhr; Igor Nenadic; Rainer Schwarting; Gerhard Schratt; Judith Alferink; Carsten Culmsee; Holger Garn; Tim Hahn; Bertram Müller-Myhsok; Astrid Dempfle; Maik Hahmann; Andreas Jansen; Petra Pfefferle; Harald Renz; Marcella Rietschel; Stephanie H Witt; Markus Nöthen; Axel Krug; Udo Dannlowski Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-09-28 Impact factor: 5.270
Authors: Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck Journal: Front Neuroendocrinol Date: 2020-08-18 Impact factor: 8.606
Authors: Gisele de Oliveira Guaita; Debora Dalla Vecchia; Roberto Andreatini; Donita L Robinson; Rainer K W Schwarting; Claudio Da Cunha Journal: Psychopharmacology (Berl) Date: 2018-03-23 Impact factor: 4.530
Authors: Ashwini Saxena; Giselli Scaini; Daniela V Bavaresco; Camila Leite; Samira S Valvassori; André F Carvalho; João Quevedo Journal: Mol Neuropsychiatry Date: 2017-10-07
Authors: Ingo Willuhn; Amanda Tose; Matthew J Wanat; Andrew S Hart; Nick G Hollon; Paul E M Phillips; Rainer K W Schwarting; Markus Wöhr Journal: J Neurosci Date: 2014-08-06 Impact factor: 6.167